Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
Benci JL, Xu B, Qiu Y, Wu TJ, Dada H, Twyman-Saint Victor C, Cucolo L, Lee DS, Pauken KE, Huang AC, Gangadhar TC, Amaravadi RK, Schuchter LM, Feldman MD, Ishwaran H, Vonderheide RH, Maity A, Wherry EJ, Minn AJ. Cell. 2016 Dec 1;167(6):1540-1554.e12. doi: 10.1016/j.cell.2016.11.022.
Summary
A new Penn Medicine preclinical study in Cell, "Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade," suggests that an existing drug known as a JAK inhibitor may help patients who don’t respond to the so-called checkpoint inhibitor immunotherapy drugs overcome that resistance.
Read the Department of Communications news release.
